TITLE

Treatment with sorafenib and sunitinib in renal cell cancer: a Swedish register-based study

AUTHOR(S)
Ambring, Anneli; Björholt, Ingela; Lesén, Eva; Stierner, Ulrika; Odén, Anders
PUB. DATE
March 2013
SOURCE
Medical Oncology;Mar2013, Vol. 30 Issue 1, p1
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Sorafenib and sunitinib are used for renal cell carcinoma (RCC). The objective was to study the treatment duration and time to death in Swedish RCC patients on sorafenib or sunitinib as first-line or monotherapy or as sequential therapy. Patients with an RCC diagnosis were identified in the Swedish Cancer Register. Information on treatment with sorafenib and sunitinib was collected from the Swedish Prescribed Drug Register, and time of death from the Cause of Death Register. Outcome measures were duration of treatment and time to death on sorafenib or sunitinib as first-line or monotherapy and sequential therapy (sorafenib-sunitinib versus sunitinib-sorafenib). Poisson regression models were used to estimate hazard ratios (HR) with 95 % confidence intervals (CI). No difference was observed for sorafenib ( n = 123 patients) versus sunitinib ( n = 261 patients) in treatment duration (HR 1.00; CI 0.80-1.24) or risk for death (HR 1.30; CI 0.91-1.85) when used as first-line or monotherapy. The same applied for sequential therapy with sorafenib-sunitinib ( n = 43 patients) versus sunitinib-sorafenib ( n = 54 patients), HR 1.47 (CI 0.71-3.02) and HR 2.01 (CI 0.86-4.68), respectively. There was a difference between the two treatments in how the duration of first-line treatment influenced the duration of second-line treatment and time to death, in favor of starting with sorafenib. In conclusion, no difference was detected between sorafenib and sunitinib in the duration of treatment or time to death when used as first-line or monotherapy. The impact of the duration of first-line treatment differed between the two sequences, and the results indicated that sorafenib as first-line treatment is a favorable choice.
ACCESSION #
85859787

 

Related Articles

  • Spotlight on cabozantinib for previously untreated advanced renal cell carcinoma: evidence to date. Bersanelli, Melissa; Leonardi, Francesco; Buti, Sebastiano // Cancer Management & Research;Sep2018, Vol. 10, p3773 

    Background: In the past few years, new drugs made their appearance in the first-line setting of treatment for metastatic renal cell carcinoma (mRCC), and cabozantinib is one among them. The present systematic review aims to point out any evidence published to date about first-line treatment with...

  • Practical management of adverse events associated with cabozantinib treatment in patients with renal-cell carcinoma. Gerendash, Benjamin S.; Creel, Patricia A. // Open Access Rheumatology: Research & Reviews;Oct2017, Vol. 9, p5053 

    Cabozantinib is an oral tyrosine-kinase inhibitor whose targets include VEGFR, MET and AXL. Cabozantinib is approved for the treatment of patients with advanced clear-cell renalcell carcinoma (RCC) who have received prior antiangiogenic therapy. In the pivotal Phase III trial of second-line RCC,...

  • Identifying Prognostic Factors for Well-Differentiated Metastatic Pancreatic Neuroendocrine Tumours: A Retrospective International Multicentre Cohort Study. Jiménez-Fonseca, Paula; Krug, Sebastian; Tamagno, Gianluca; Fierro Maya, Felipe; Monléon Getino, Antonio; Rodriguez Casado, Clara Isabel; Costa, Frederico; de Herder, Wouter W.; Jann, Henning // Neuroendocrinology;Jan2019, Vol. 107 Issue 4, p315 

    Pancreatic neuroendocrine tumours (pNETs) represent rare neoplasms of all NETs often presenting without functional activity. Many sporadic non-functioning pNET patients are already metastatic at the time of diagnosis, and the therapeutic approach to such patients is mostly palliative. In this...

  • Pfizer Provides Topline Results From Phase 3 Study Of Torisel(r) As Second-Line Treatment In Advanced Renal Cell Carcinoma (RCC).  // Biomedical Market Newsletter;5/18/2012, Vol. 21, p1 

    The article provides information on the Phase 3 INTORSECT study conducted by Pfizer Inc. to evaluate TORISEL (®) (temsirolimus) in patients with advanced renal cell carcinoma (RCC). The study showed that the results did not meet the primary endpoint of prolonging progression free survival...

  • Sorafenib.  // AHFS Consumer Medication Information;Jan2020, p1 

    Sorafenib is used to treat advanced renal cell carcinoma (a type of cancer that begins in the kidneys). Sorafenib is also used to treat unresectable hepatocellular carcinoma (a type of liver cancer that cannot be treated with surgery). Sorafenib is in a class of medications called multikinase...

  • Downsizing a Thrombus of Advanced Renal Cell Carcinoma in a Presurgical Setting with Sorafenib. Takeda, Hirokazu; Nakano, Yojiro; Kashiwagi, Yuhta; Yoshino, Yasushi; Gotoh, Momokazu // Urologia Internationalis;Mar2012, Vol. 88 Issue 2, p235 

    A 53-year-old man presented with fever, 15 kg weight loss, ECOG performance status 0, and 12 × 9.5 cm renal tumor with an associated level II (near level III) tumor thrombus extending into the vena cava. We offered a presurgical targeted therapy to downsize the thrombus and primary tumor,...

  • Adjuvant vaginal cuff brachytherapy for high-risk, early stage endometrial cancer. Eldredge-Hindy, Harriet Belding; Eastwick, Gary; Rani Anne, Pramila; Rosenblum, Norman G.; Schilder, Russell J.; Chalian, Raffi; Zibelli, Allison M.; Kim, Christine H.; Den, Robert // Journal of Contemporary Brachytherapy;2014, Vol. 6 Issue 3, p262 

    Purpose: To report outcomes following adjuvant high-dose-rate vaginal brachytherapy (VBT) with or without chemotherapy for high-intermediate risk (HIR) and high-risk, early stage endometrial cancer as defined in Gynecologic Oncology Group trial 0249. Material and methods: From May 2000 to...

  • Immunotherapy of Genitourinary Malignancies. Teruo Inamoto; Haruhito Azuma // Journal of Oncology;2012, p1 

    Most cancer patients are treated with some combination of surgery, radiation, and chemotherapy. Despite recent advances in local therapy with curative intent, chemotherapeutic treatments for metastatic disease often remain unsatisfying due to severe side effects and incomplete long-term...

  • New challenges in kidney cancer therapy: sunitinib. Izzedine, H; Billemont, B; Thibault, F; Rixe, O // Annals of Oncology;Sep2007 Supplement 9, Vol. 18, pix83 

    The article explores the challenges posed by the use of sunitinib in kidney cancer. It describes the overall incidence of renal cell carcinoma (RCC) in the U.S., along with the biology of RCC. It also explains the mechanism of action of sunitinib, including its clinical pharmacology. In...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics